GSK agreed to acquire Nuvalent for about $10.6 billion in cash, securing two late-stage lung cancer medicines under FDA review: zidesamtinib (ROS1) and neladalkib (ALK). The acquisition reinforces GSK’s push to build a lung-cancer franchise and leverages a platform of targeted kinase programs with potential near-term launches if FDA approvals arrive. Under deal terms, GSK will pay $124 per share to Nuvalent shareholders, a premium to Nuvalent’s recent trading levels. GSK also expects to fund the transaction through new and existing debt and anticipates deal profitability starting in 2027. FDA decision timelines are set for September 18, 2026 for zidesamtinib and November 27, 2026 for neladalkib, both carrying breakthrough and orphan drug designations. The acquisition also includes earlier programs, providing additional options for extending the lung cancer portfolio beyond first approvals.